ArticleVaccines2025

Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study.

Fabrizio Nelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.